BERLIN (dpa-AFX) - Sartorius Stedim Biotech (SARTF), a pharmaceutical and laboratory equipment supplier, on Thursday reported a significant surge in income for the first quarter, amidst a rise in sales, supported by a firm demand for the company's products and services.
For the first three-month period of 2022, Sartorius reported a profit of 270.1 million euros or 2.21 euros per share, compared with 125.8 million euros or 1.64 euros per share, reported for the same period a year ago. Underlying net profit for the period was also rose to 203.4 million euros, from 151.3 million euros of last year.
The German firm also posted an increase in EBITDA at 303.7 million euros as against 231.6 million euros, recorded for first quarter of 2021.
For the first quarter, the Göttingen-based lab equipment supplier generated sales revenue of 862.5 million euros, versus 655.2 million euros posted for the first three-month period of last year.
Looking ahead, for the fiscal 2022, the company expects a rise in its consolidated sales revenue by about 15 percent to 19 percent, with non-organic growth from acquisitions projected to contribute about 2 percentage points.
The company's underlying EBITDA margin is expected to reach over 35 percent for the full year.
Copyright(c) 2022 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
© 2022 AFX News
